RecruitingPulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Sponsor: 35Pharma Inc
You may qualify if…
- ✓ Participants are eligible to be included in the study only if they meet all of the following criteria:
- ✓ 1. Male and female participants, 18 years of age and older.
- ✓ 2. Body Mass Index (BMI) 18.5 and 40 kg/m2 and body weight at or below 120 kg.
- ✓ 3. Baseline RHC performed during the Screening Period documenting:
- ✓ 1. A minimum PVR of ≥ 5 Wood units (WU) or ≥ 400 dyn·sec·cm-5 and,
- ✓ 2. A pulmonary artery wedge pressure (PAWP) of ≤ 15 mm Hg.
- ✓ 4. Diagnosis of WHO pulmonary arterial hypertension (PAH) Group 1.
- ✓ 5. Symptomatic PAH classified as WHO Functional class II to IV.
You may not qualify if…
- ✕ 1. PH WHO Groups 2, 3, 4 or 5.
- ✕ 2. Hospitalization for any worsening medical condition or major surgery within 4 weeks prior to screening.
- ✕ 3. Any symptomatic coronary disease events.
- ✕ 4. History of heart transplant or on heart transplant list.
- ✕ 5. Uncontrolled systemic hypertension.
- ✕ 6. History of restrictive, constrictive or congestive cardiomyopathy.
- ✕ 7. History of significant mitral regurgitation or aortic regurgitation valvular disease.
- ✕ 8. Untreated or poorly controlled moderate or severe obstructive sleep apnea.
Where it's recruiting
Florida
Tampa
Rhode Island
Providence
Source: ClinicalTrials.gov · NCT07143448 · last updated 2026-09-11